Search Results

TOP 10 ARTICLES THAT CAPTURED YOUR ATTENTION IN 2022!

Funding innovative vision research is at the heart of Fighting Blindness Canada (FBC). Throughout the year, our monthly e-newsletter has shared articles and publications showcasing the amazing research and advocacy work taking...

THEIR PARENTS THOUGHT THEY WERE AFRAID OF THE DARK. THEN THESE TWINS LEARNED THE TRUTH — AND THE FIGHT TO SAVE THEIR SIGHT BEGAN

Nathan and Andre needed a game-changing gene-specific therapy. But the costs were astronomical and the parents were at a loss. Here’s how I witnessed their story go from tragic to triumphant. Twins...

NAC ATTACK: A PHASE III CLINICAL TRIAL TO TEST AN ORAL THERAPY FOR RETINITIS PIGMENTOSA

Starting in 2023, a new clinical trial called NAC Attack will be launched to test an oral medication, N-acetylcysteine (NAC), as a potential therapy for patients with retinitis pigmentosa (RP). NAC Attack...

DEVELOPING A NEW THERAPY FOR AGE-RELATED MACULAR DEGENERATION AND DIABETIC RETINOPATHY.

Dr. Sachdev Sidhu (University of Toronto) is a biomedical engineer with extensive experience in drug development. Dr. Sidhu established the Toronto Recombinant Antibody Centre (TRAC) which houses a state-of-the-art platform to generate...

FBC SCIENTISTS COLLABORATE TO IDENTIFY NEW GENE FOR RETINITIS PIGMENTOSA

Teamwork really does make the dream work! We are excited to share news of a Fighting Blindness Canada (FBC) funded discovery recently published in the journal Science Advances achieved through a collaboration...

WELCOME TO VIEW POINT TORONTO

Jump to: Welcome | Spotlight on FBC | Program | Meet the Speakers | Sponsors WELCOME Welcome, everyone, to View Point Toronto! Thank you for being here, for your support, and for...